Catalent (CTLT) : The consensus on Catalent (CTLT) based on 9 analyst recommendation on the company stock is 2.11, which is interpreted as a Buy recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 4 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 5 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.
Catalent (CTLT) : The highest level Catalent (CTLT) is projected to reach is $31 for the short term and the lowest estimate is at $23. The consolidated price target from 5 rating analysts who initiate coverage on the stock is $26.5 and the possibility the share price can swing is $2.87.
For the current week, the company shares have a recommendation consensus of Buy.
Catalent (NYSE:CTLT): During Tuesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $23.52 and $23.35 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $24.00. The buying momentum continued till the end and the stock did not give up its gains. It closed at $23.74, notching a gain of 0.85% for the day. The total traded volume was 1,585,369 . The stock had closed at $23.54 on the previous day.
Catalent, Inc. is a provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. The Companys segments include Oral Technologies, Medication Delivery Solutions, and Development and Clinical Services. The Oral Technologies segment provides advanced oral delivery technologies, including formulation, development and manufacturing of oral dose forms for prescription and consumer health products across all phases of a molecules lifecycle. The Medication Delivery Solutions segment provides formulation, development and manufacturing services for delivery of drugs and biologics, administered through injection, inhalation and ophthalmic routes, using both traditional and advanced technologies. The Development and Clinical Services segment provides manufacturing, packaging, storage and inventory management for drugs and biologics in clinical trials.